- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Novartis steps up its pain management drug portfolio
To buy U.S. Australian biotech firm Spinifex PharmaceuticalsSwiss Drugmaker Novartis has decided to invest in the potential of new medicines, considering the investor confidence across the drug sectors at present. Their commitment is reiterated in its recent acquisition of Australian biotech firm Spinifex Pharmaceuticals, to boost its presence in pain management. Novartis is reported to have...
Swiss Drugmaker Novartis has decided to invest in the potential of new medicines, considering the investor confidence across the drug sectors at present. Their commitment is reiterated in its recent acquisition of Australian biotech firm Spinifex Pharmaceuticals, to boost its presence in pain management. Novartis is reported to have made the acquisition at $200 million upfront, and the rest of the amount to be made based on clinical developments and regulatory milestones. The complete deal is expected to be closed by the end of this year.
This investment led by Novartis will give the company rights to acquire Spinifex's experimental neuropathic pain drug EMA401, which can be consumed to treat post-herpetic neuralgia (PHN), a painful condition some people get after shingles. The clinical trial for the drug use is in the mid-stage Phase II, and will get a further boost by the acquisition.
Importantly, the results published in The Lancet medical journal last year showed no central nervous system side effects or any serious adverse events Novartis also intends to start Phase IIb clinical trials in patients with PHN or another condition called painful diabetic neuropathy, which is caused by diabetes.
"Neuropathic pain is a chronic and debilitating condition with high unmet need. EMA401 could provide a novel, differentiated treatment approach," said David Epstein, head of Novartis Pharmaceuticals. (as reported by Reuters).
Novartis has made recent advances in offering treatment using new drug applications including the widely anticipated heart failure medicine LCZ696 and a recently launched psoriasis injection called Cosenty
Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country.She is a member of the Association of Healthcare Journalists. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751